Drug guidance
Sumatriptan for the treatment of acute migraine attacks
Condition
Neurology
3 May 2017
Published on 03 May 2017
Last Updated on 03 May 2017
Guidance Recommendations
Following an evaluation of sumatriptan for the treatment of acute migraine attacks, sumatriptan 50mg tablet is recommended for listing on the MOH Standard Drug List 2 (SDL2) by the MOH Drug Advisory Committee in view of its clinically superior outcomes when used in combination with naproxen compared with either sumatriptan or naproxen monotherapy, and the low cost of subsidy.
This recommendation means that subsidies will apply to sumatriptan for the indications registered in Singapore:
Acute relief of migraine attacks with or without aura, including the acute treatment of migraine attacks associated with the menstrual period in women.